Compare LMB & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | NBTX |
|---|---|---|
| Founded | 1901 | 2003 |
| Country | United States | France |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2014 | 2018 |
| Metric | LMB | NBTX |
|---|---|---|
| Price | $72.72 | $51.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $116.67 | $36.00 |
| AVG Volume (30 Days) | ★ 310.6K | 68.3K |
| Earning Date | 05-05-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $646,804,000.00 | N/A |
| Revenue This Year | $15.96 | $58.17 |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $207.75 | ★ N/A |
| Revenue Growth | ★ 24.68 | N/A |
| 52 Week Low | $65.08 | $3.64 |
| 52 Week High | $154.04 | $57.14 |
| Indicator | LMB | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 65.31 |
| Support Level | $71.40 | $19.22 |
| Resistance Level | $85.38 | N/A |
| Average True Range (ATR) | 6.95 | 3.29 |
| MACD | -2.73 | 1.71 |
| Stochastic Oscillator | 3.91 | 77.12 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.